Truist Financial Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia
Promising Developments and Financial Strength Support Buy Rating for Larimar Therapeutics
JonesTrading Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $10
Truist Financial Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
Larimar Therapeutics Analyst Ratings
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $17
Analysts' Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
William Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)
Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
Truist Financial Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $18
Truist Sees 'Significant Upside' for Larimar Therapeutics, Starts With a Buy
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target